Physician profile
John Evan Sy
NPI 1639435738
$1,631.39
in general payments reported to CMS, 2019-2025
19 companies · $660 in 2025
The $660 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $143 · 2022: $36.20 · 2023: $61.71 · 2024: $306 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.03 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $338.54 | 2019-2024 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $203.99 | 2020-2025 | Jynarque |
| Akebia Therapeutics INC | $147.59 | 2019-2025 | Vafseo |
| Novartis Pharmaceuticals Corporation | $125.26 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $125.02 | 2024-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.89 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $106.94 | 2025 | Rivfloza, Ozempic |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $83.95 | 2020-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $81.39 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $51.69 | 2024-2025 | |
| Genentech USA, INC. | $34.39 | 2025 | Gazyva |
| Mallinckrodt Hospital Products INC. | $33.48 | 2025 | Acthar |
| Alnylam Pharmaceuticals INC. | $32.19 | 2025 | Oxlumo |
| Amgen INC. | $29.89 | 2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $29.70 | 2024 | Lokelma |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.50 | 2025 | Benlysta |
| Ardelyx, INC. | $22.54 | 2025 | Ibsrela |
| Scpharmaceuticals INC. | $22.45 | 2025 | |
| Lilly USA, LLC | $17.99 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.